…at Hansa Biopharma we envision a world where all patients with rare immunologic diseases can lead long and healthy lives...

ABOUT HANSA BIOPHARMA

Hansa Biopharma is leveraging its proprietary enzyme technology platform to develop immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy and cancer. The Company's lead product candidate, imlifidase, is an antibody cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. Imlifidase has been granted conditional approval in the European Union for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Commercial launch in select European countries is expected in the fourth quarter of 2020. Hansa's research and development program is advancing the Company's enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases, gene therapy and oncology. Hansa Biopharma is based in Lund, Sweden and has operations in EU and the US.

BROAD PIPELINE IN TRANSPLANTATION AND AUTOIMMUNE DISEASES

Candidate	Indication	Research/ Preclinical	Phase 1	Potentially Pivotal program/ Phase 2	Phase 3	Marketing Authorization	Marketed
Imlifidase	**EU** Kidney transplantation in highly sensitized patients [1,2]						*)
	US Kidney transplantation in highly sensitized patients [1,2]				**)		
	Anti-GBM antibody disease (investigator-initiated study)						
	Antibody mediated kidney transplant rejection (AMR)						
	GBS (Guillain Barre Syndrome)						
	Limb-Girdle (LGMD) & Duchenne (DMD) (Pre-treatment ahead of gene therapy with Sarepta)						
NiceR	Recurring treatment in autoimmune disease, transplantation and oncology						
EnzE	Cancer immunotherapy						

Completed
Ongoing

[1] Results from the Phase 1 study have been published, Winstedt el al. (2015) PLOS ONE 10(7)
[2] Lorant et al American Journal of Transplantation and 03+04 studies (Jordan et al New England Journal of Medicine)
3 Investigator-initiated study by Mårten Segelmark, Professor at the universities in Linköping and Lund
*) The EU Commission has granted conditional approval for imlifidase in highly sensitized kidney transplant patients. A post-approval study will commence in parallel with the launch
**) FDA: Proposed study protocol submitted June 2020. Discussions are currently ongoing with the FDA. Once the final protocol has been agreed upon, Hansa Biopharma will proceed to set up centers in the US and start to enroll patients. Given the continued impact of the COVID-19 pandemic and the timeline for the finalization of the study protocol Hansa expect recruitment of the first patient to be in H1 2021)

STRATEGIC PRIORITIES

- Establish a commercial and medical infrastructure in Europe ahead of commercial launch
- Marketing authorization obtained in Europe for imlifidase as a treatment for highly sensitized patients to enable kidney transplantation. Conduct a new randomized, controlled study in the US in the context of KAS to support a BLA filing by 2023
- Investigate the potential of imlifidase in autoimmune indications and post transplantation
- Advance a new set of immunomodulatory enzymes designed for repeat dosing in relapsing diseases (NiceR) into clinical development
- Explore potential combination therapies with imlifidase in oncology and in gene therapy in patients with neutralizing antibodies

ANTICIPATED FUTURE MILESTONES



Updated 2020-10-22

Hansa Biopharma AB P.O. Box 785 SE-220 07 Lund, Sweden
www.hansabiopharma.com

HANSA BIOPHARMA

COMPANY FACTS

Founded	2007
Stock Exchange	NASDAQ Stockholm (HNSA)
Headquarter	Lund, Sweden
Operations	Europe and the US
Employees	~80 (~2/3 in R&D)
Key Executives	Ulf Wiinberg, Chairman
	Søren Tulstrup, President & CEO
	Donato Spota, SVP & CFO
	Christian Kjellman, SVP & CSO/COO

MARKET DATA (Q3 2020)

Market Cap	SEK ~11bn (USD ~1.25bn)	
52 Week Range	SEK 59-289	
Avg. Daily Turnover	vol. 565k shares	
Shares Outstanding	45m	
Top 5 Shareholders	Consonance Capman	6.0%
	Redmile Group	5.2%
	NXT2B	4.8%
	Invesco	4.4%
	Thomas Olausson	3.9%

STOCK CHART (1Y)



KEY FINANCIALS

SEKm	9M 2018	9M 2019	9M 2020*
Revenue	2m	2m	2m
R&D cost	-112m	-135m	-177m
Net loss	-167m	-249m	-315m
Cash & Short investment	483m	680m	1,476m
Operating Cash Flow	-147m	-260m	-194m
Employees	49	64	80

** Unaudited*

CALENDAR

Oct 29, 2020	**Hansa Biopharma Capital Markets Day, Copenhagen and virtual**
Nov 17, 2020	Bryan Garnier Healthcare Conference, Paris
Nov 18, 2020	Jefferies Healthcare Conference, London
Nov 25, 2020	Ökonomisk Ugebrev Life Science Conf, CPH
Feb 2, 2021	**Interim report Jan-Dec 2020**
April 22, 2021	**Interim report for Jan-Mar 2021**
July 15, 2021	**Interim report for Jan-Jun 2021**
Oct 21, 2021	**Interim report for Jan-Sep 2021**

CONTACTS

Klaus Sindahl
Head of Investor Relations
M: +46(0)709-298 269
klaus.sindahl@hansabiopharma.com

Katja Margell
Head of Corp. Comms.
M: +46(0)768-198 326
katja.margell@hansabiopharma.com

IMLIFIDASE – A NOVEL APPROACH TO ELIMINATE PATHOGENIC IgG

Origins from Streptococcus pyogenes



Imlifidase, a unique IgG antibody-cleaving enzyme



Imlifidase inactivates IgG in 2 hours



OUR EQUITY STORY

Imlifidase is a unique IgG antibody-cleaving enzyme with a rapid onset of action and high specificity for inactivation of IgG in patients with rare immunologic diseases

Preparing for potential European launch of imlifidase following conditional approval by the EU Commission in 2020 for imlifidase in highly sensitized kidney transplant patients in the European Union

Evolution into a fully integrated commercial stage biopharmaceutical company. Controlling the full value chain from early discovery through commercialization to maximize the value creation and capture

Leveraging our proprietary antibody cleaving enzyme technology. Advancing our pipeline with three Phase 2 programs in transplantation and acute autoimmune diseases

New set of modified enzymes under development (NiceR program) for repeat dosing; potentially enabling treatment in relapsing diseases and oncology

Exploring potential combination therapies in oncology with IgG-modulating enzymes and gene therapy in patients with neutralizing antibodies through potential partnerships



POTENTIAL INDICATION UNIVERSE



* US: Study protocol submitted June 2020, study expected to be initiated H1 2021. The new clinical study could support BLA submission by 2023

HANSA BIOPHARMA